Evidence map›Paper›PMID 31427737›Full record

ArticleOncogene2019

MUC13 promotes the development of colitis-associated colorectal tumors via β-catenin activity.

Yong Hua Sheng, Kuan Yau Wong, Inge Seim, Ran Wang, Yaowu He, Andy Wu, Maya Patrick, Rohan Lourie, Veronika Schreiber, Rabina Giri and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. [Analysis of therapeutic mechanism ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
  14. Article
  15. IL-22-ActivatedCells · 2023
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 2 countries.

Yong Hua ShengInflammatory Disease Biology and Therapeutics Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.ORCID http://orcid.org/0000-0002-4623-9098
Kuan Yau WongInflammatory Disease Biology and Therapeutics Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Inge SeimInflammatory Disease Biology and Therapeutics Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Ran WangInflammatory Disease Biology and Therapeutics Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Yaowu HeCancer Biology Group, Mater Research Institute, University of Queensland, Woolloongabba, Brisbane, QLD, 4101, Australia.
Andy WuBones and Immunology Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Maya PatrickInflammatory Disease Biology and Therapeutics Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Rohan LourieInflammatory Disease Biology and Therapeutics Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Veronika SchreiberInflammatory Bowel Diseases Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Rabina GiriInflammatory Bowel Diseases Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Choa Ping NgInflammatory Disease Biology and Therapeutics Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Amirali PopatInflammatory Disease Biology and Therapeutics Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
John HooperCancer Biology Group, Mater Research Institute, University of Queensland, Woolloongabba, Brisbane, QLD, 4101, Australia.ORCID http://orcid.org/0000-0003-1054-8486
Gregor KijankaImmune Profiling & Cancer Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Timothy H FlorinInflammatory Bowel Diseases Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Jakob BegunInflammatory Bowel Diseases Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia.
Kristen J RadfordCancer Immunotherapies Group, Mater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4101, Australia.
Sumaira HasnainInflammatory Disease Biology and Therapeutics Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia. sumaira.hasnain@mater.uq.edu.au.ORCID http://orcid.org/0000-0001-8577-8628
Michael A McGuckinInflammatory Disease Biology and Therapeutics Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, 4102, Australia. michael.mcguckin@unimelb.edu.au.ORCID http://orcid.org/0000-0002-8375-2675
Translational Research Institute · AUThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many adenocarcinomas, including colorectal cancer (CRC), overexpress the MUC13 cell surface mucin, but the functional significance and mechanisms are unknown. Here, we report the roles of MUC13 in colonic tumorigenesis and tumor progression. High-MUC13 expression is associated with poor survival in two independent patient cohorts. In a comprehensive series of in vivo experiments, we identified a critical role for MUC13 in the development of this malignancy, by promoting survival and proliferation of tumor-initiating cells and driving an immunosuppressive environment that protects tumors from checkpoint inhibitor immunotherapy. In Muc13-deficient mice, fewer tumors are generated after exposure to carcinogens and inflammation, they have markedly reduced β-catenin signaling, have more tumor-infiltrating CD103

Indexed as

Gene Expression Regulation, NeoplasticAnimalsAntigens, SurfaceApoptosisbeta CateninBiomarkers, TumorCarcinogenesisCell ProliferationCohort StudiesColitisColorectal NeoplasmsEpidermal Growth FactorHumansMiceMice, Inbred C57BLMice, KnockoutAntigens, Surfacebeta CateninBiomarkers, TumorEpidermal Growth FactorLy64 protein, mouseMUC13 protein, humanMucins

Identifiers

PMID31427737
OpenAlexW2969280377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.